Our findings regarding the prognostic significance of HER2 classification indicated that patients with HER2-low BC, particularly within the HR+ subgroup, exhibited a more favorable prognosis compared to those with HER2-ultralow and HER2+ tumors. Here, ERBB2 is linked to breast cancer.